Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML)

Leukemia Research

Volumn 33, Issue 4, 2009, Pages 551-555

  Chomel, Jean Claude ^a,b   Sorel, Nathalie ^a,b   Bonnet, Marie Laure ^a,b   Bertrand, Angelina ^a,b   Brizard, Françoise ^a   Saulnier, Pierre Jean ^a   Roy, Lydia ^a,b   Guilhot, François ^a,b   Turhan, Ali G ^a,b  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

BCR ABL; CML; Monitoring; T315I mutation

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; DASATINIB; HYDROXYUREA; IMATINIB; NILOTINIB;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MUTATION; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 60249092358     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.08.018     Document Type: Article

References (9)

1. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med 355 (2006) 2408-2417
2. O'Hare T., Eide C.A., and Deininger M.W. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110 (2007) 2242-2249
3. Sorel N., Chazelas F., Brizard A., and Chomel J.C. Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients. Clin Chem 51 (2005) 1263-1266
4. Gabert J., Beillard E., van der VeV, Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 17 (2003) 2318-2357
5. Gruber F.X., Lamark T., Anonli A., Sovershaev M.A., Olsen M., Gedde-Dahl T., et al. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 19 (2005) 2159-2165
6. Johansen LE. Targeted detection of mutations associated with imatinib-resistance. Strategies to increase sensitivity and specificity. Master thesis in pharmacology. Tromsø, Norway: Department of Pharmacology, Institute of Pharmacy; 2006.
7. Hayette S., Michallet M., Baille M.L., Magaud J.P., and Nicolini F.E. Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients. Leukemia Res 29 (2005) 1073-1077
8. Cortes J., Jabbour E., Kantarjian H., Yin C.C., Shan J., O'Brien S., et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 110 (2007) 4005-4011
9. Jabbour E., Kantarjian H., Jones D., Breeden M., Garcia-Manero G., O'Brien S., et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112 (2008) 53-55